Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction.

Baker JV, Neuhaus J, Duprez D, Freiberg M, Bernardino JI, Badley AD, Nixon DE, Lundgren JD, Tracy RP, Neaton JD; INSIGHT SMART Study Group.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):128-34. doi: 10.1097/QAI.0b013e318252f99f.

2.

Marker of Endothelial Dysfunction Asymmetric Dimethylarginine Is Elevated in HIV Infection but Not Associated With Subclinical Atherosclerosis.

Haissman JM, Haugaard AK, Knudsen A, Kristoffersen US, Seljeflot I, Pedersen KK, Lebech AM, Hasbak P, Kjær A, Ostrowski SR, Gerstoft J, Trøseid M, Nielsen SD.

J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):507-513.

PMID:
27509250
3.

Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.

Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD; INSIGHT SMART Study Group.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):36-43. doi: 10.1097/QAI.0b013e3181f7f61a.

4.

Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral therapy.

Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, Fuchs D.

Antivir Ther. 2012;17(6):1021-7. doi: 10.3851/IMP2304. Epub 2012 Aug 15.

PMID:
22892398
5.

Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection.

Parikh RV, Scherzer R, Nitta EM, Leone A, Hur S, Mistry V, Macgregor JS, Martin JN, Deeks SG, Ganz P, Hsue PY.

AIDS. 2014 Feb 20;28(4):511-9. doi: 10.1097/QAD.0000000000000124.

6.

Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals.

Parikh RV, Scherzer R, Grunfeld C, Nitta EM, Leone A, Martin JN, Deeks SG, Ganz P, Hsue PY.

Atherosclerosis. 2013 Jul;229(1):246-52. doi: 10.1016/j.atherosclerosis.2013.04.025. Epub 2013 Apr 30.

7.

The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection.

O'Halloran JA, Dunne E, Gurwith M, Lambert JS, Sheehan GJ, Feeney ER, Pozniak A, Reiss P, Kenny D, Mallon P.

HIV Med. 2015 Nov;16(10):608-19. doi: 10.1111/hiv.12270. Epub 2015 Jun 25.

8.

Asymmetric dimethylarginine and coronary artery calcium scores are increased in patients infected with human immunodeficiency virus.

Jang JJ, Berkheimer SB, Merchant M, Krishnaswami A.

Atherosclerosis. 2011 Aug;217(2):514-7. doi: 10.1016/j.atherosclerosis.2011.03.035. Epub 2011 Apr 5.

PMID:
21549379
9.

Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.

Baker JV, Neuhaus J, Duprez D, Cooper DA, Hoy J, Kuller L, Lampe FC, Liappis A, Friis-Moller N, Otvos J, Paton NI, Tracy R, Neaton JD; INSIGHT SMART Study Group.

AIDS. 2011 Nov 13;25(17):2133-42. doi: 10.1097/QAD.0b013e32834be088.

10.

Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy.

Achhra AC, Phillips A, Emery S, MacArthur RD, Furrer H, De Wit S, Losso M, Law MG; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Management of Antiretroviral Therapy (SMART) and Flexible Initial Retrovirus Suppressive Therapies (FIRST) study groups.

HIV Med. 2015 Aug;16(7):449-54. doi: 10.1111/hiv.12258. Epub 2015 May 11.

11.

Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria.

Ferroni P, Guagnano MT, Falco A, Paoletti V, Manigrasso MR, Michetti N, Santilli F, Guadagni F, Basili S, Davì G.

Clin Sci (Lond). 2008 Mar;114(6):449-55.

PMID:
17988217
12.

Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.

Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, García Morillo JS, Egido J, Noval ML, Ferrando-Martinez S, Blanco-Colio LM, Genebat M, Villar JR, Moreno-Luna R, Moreno JA.

PLoS One. 2014 Mar 4;9(3):e90541. doi: 10.1371/journal.pone.0090541. eCollection 2014.

13.

HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation.

Hove-Skovsgaard M, Gaardbo JC, Kolte L, Winding K, Seljeflot I, Svardal A, Berge RK, Gerstoft J, Ullum H, Trøseid M, Nielsen SD.

BMC Infect Dis. 2017 Mar 29;17(1):234. doi: 10.1186/s12879-017-2334-8.

14.

Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.

Rasmussen TA, Tolstrup M, Melchjorsen J, Frederiksen CA, Nielsen US, Langdahl BL, Østergaard L, Laursen AL.

BMC Infect Dis. 2011 Oct 4;11:267. doi: 10.1186/1471-2334-11-267.

15.

A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy.

Graham SM, Rajwans N, Tapia KA, Jaoko W, Estambale BB, McClelland RS, Overbaugh J, Liles WC.

BMC Infect Dis. 2013 Jun 4;13:263. doi: 10.1186/1471-2334-13-263.

16.

Risk factors for chronic kidney disease do not influence the serum levels of asymmetric dimethylarginine in HIV-1-infected patients without significant renal disease.

Szymanek-Pasternak A, Szymczak A, Zalewska M, Małyszczak K, Knysz B.

Pol Arch Med Wewn. 2016 Aug 18;126(9):672-680. doi: 10.20452/pamw.3508. Epub 2016 Aug 18.

17.

Monocyte activation, but not microbial translocation, is independently associated with markers of endovascular dysfunction in HIV-infected patients receiving cART.

Pedersen KK, Manner IW, Seljeflot I, Kvale D, Os I, Gerstoft J, Nielsen SD, Trøseid M.

J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):370-4. doi: 10.1097/QAI.0000000000000339.

PMID:
25226210
18.

Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers.

Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, Fuchs D.

Pharmacol Res. 2009 Dec;60(6):508-14. doi: 10.1016/j.phrs.2009.07.009. Epub 2009 Aug 3.

PMID:
19651212
19.

The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels.

Uzun H, Konukoglu D, Besler M, Erdenen F, Sezgin C, Muderrisoglu C.

Clin Invest Med. 2008;31(1):E1-7.

PMID:
18312743
20.

Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease.

Ledwaba L, Tavel JA, Khabo P, Maja P, Qin J, Sangweni P, Liu X, Follmann D, Metcalf JA, Orsega S, Baseler B, Neaton JD, Lane HC; Project Phidisa Biomarkers Team.

PLoS One. 2012;7(3):e24243. doi: 10.1371/journal.pone.0024243. Epub 2012 Mar 20.

Supplemental Content

Support Center